These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23670484)

  • 21. Viral hepatitis C in 2014--the beginning of the end?
    Prelipcean CC; Gogălniceanu P; Mihai C
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):272-8. PubMed ID: 25076687
    [No Abstract]   [Full Text] [Related]  

  • 22. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients.
    Wilby KJ; Greanya ED; Ford JA; Yoshida EM; Partovi N
    Ann Hepatol; 2012; 11(2):179-85. PubMed ID: 22345334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects.
    Florian J; Jadhav PR; Amur S; Ayala R; Harrington P; Mishra P; O'Rear J; Pacanowski M; Robertson S; Singer M; Soon G; Zeng W; Murray J
    Hepatology; 2013 Mar; 57(3):903-7. PubMed ID: 22610696
    [No Abstract]   [Full Text] [Related]  

  • 24. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
    Venkatraman S
    Trends Pharmacol Sci; 2012 May; 33(5):289-94. PubMed ID: 22521415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-drug interactions in the treatment of HCV among people who inject drugs.
    Mauss S; Klinker H
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S125-8. PubMed ID: 23884060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hepatitis C update: what has changed? What can we expect in the near future?].
    Geier A
    MMW Fortschr Med; 2013 Nov; 155(19):59-62. PubMed ID: 24475674
    [No Abstract]   [Full Text] [Related]  

  • 27. Hepatitis drug reduces effects of HIV medications.
    Kuehn BM
    JAMA; 2012 May; 307(20):2138. PubMed ID: 22618906
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
    Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
    Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus therapy update 2013.
    Casey LC; Lee WM
    Curr Opin Gastroenterol; 2013 May; 29(3):243-9. PubMed ID: 23563981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.
    Susser S; Welsch C; Wang Y; Zettler M; Domingues FS; Karey U; Hughes E; Ralston R; Tong X; Herrmann E; Zeuzem S; Sarrazin C
    Hepatology; 2009 Dec; 50(6):1709-18. PubMed ID: 19787809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C.
    Smith LS; Nelson M; Naik S; Woten J
    Ann Pharmacother; 2011 May; 45(5):639-48. PubMed ID: 21558488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low SVR rates in clinical practice for treating genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir.
    Dubin PH; Sclair SN; Rico R; Boehme AK; Chen EY; Martin P; Lee WM
    Dig Dis Sci; 2015 Jan; 60(1):272-4. PubMed ID: 25283376
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
    Hulskotte EG; Feng HP; Xuan F; van Zutven MG; Treitel MA; Hughes EA; O'Mara E; Youngberg SP; Wagner JA; Butterton JR
    Clin Infect Dis; 2013 Mar; 56(5):718-26. PubMed ID: 23155151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA bridging analyses confirmed in clinical trial.
    Mishra P; Florian J; Murray J
    Hepatology; 2014 Dec; 60(6):2134. PubMed ID: 24591059
    [No Abstract]   [Full Text] [Related]  

  • 35. HCV protease inhibitors bring new options for patients.
    Traynor K
    Am J Health Syst Pharm; 2011 Aug; 68(15):1372, 1374, 1379. PubMed ID: 21785015
    [No Abstract]   [Full Text] [Related]  

  • 36. Prompt arrival of antivirals against hepatitis C for HIV patients.
    Barreiro P; Vispo E
    AIDS Rev; 2010; 12(4):242-3. PubMed ID: 21344779
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of the transplant recipient with chronic hepatitis C.
    Burton JR; Everson GT
    Clin Liver Dis; 2013 Feb; 17(1):73-91. PubMed ID: 23177284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A major advance in treating hepatitis C.
    Johns Hopkins Med Lett Health After 50; 2011 Dec; 23(10):6. PubMed ID: 22216468
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacokinetic interactions of telaprevir with other drugs].
    Berenguer Berenguer J; González-García J
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():37-48. PubMed ID: 24063902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir.
    D'Avolio A; De Nicolò A; Agnesod D; Simiele M; Mohamed Abdi A; Dilly Penchala S; Boglione L; Cariti G; Di Perri G
    J Pharm Biomed Anal; 2013 May; 78-79():217-23. PubMed ID: 23501442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.